Médecins Sans Frontières releases a factsheet outlining the current scenario of diagnosing TB in children and making recommendations to test developers for needed improvements.

Médecins Sans Frontières issues a report offering case studies of two critical TB tools, GeneXpert and delamanid, and outlining actions that the corporations making them need to take to unlock access to these tools.

Historic price reductions will allow millions more people to receive TB prevention, treatment and testing.

NEW YORK/GENEVA, MAY 26, 2023 — The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes today’s passage of a resolution at the 76th annual United Nations World Health Assembly to strengthen countries’ diagnostic testing capacity. With almost half of the global population having little or no access to disease testing, this resolution is an essential step towards improving global access to diagnostic tools, said MSF. Increasing access to testing for a variety of diseases is critical as it is necessary in order to put people on the best medical treatments possible.

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many.

On Friday 24th March, the MSF Science Twitter account will be hosting a Twitter Spaces event (a live audio discussion) on ‘Treating drug-resistant tuberculosis: the past, present and future’!

Médecins Sans Frontières urges the Indian Patent Office to reject the secondary patent application filed by Johnson & Johnson to prevent the company from extending its monopoly on bedaquiline beyond the primary patent’s expiry in July 2023.

With newer TB drugs to go off patent in 2023, MSF calls on Johnson & Johnson, Otsuka, and TB Alliance to remove additional barriers blocking generic manufacturers from entering the market.

A shortage of TB tests at this critical juncture will be disastrous.

In an article published in the journal BMJ Global Health, authors from the Médecins Sans Frontières (MSF) Access Campaign analyse the development and approval of two newer drugs for treating drug-resistant tuberculosis (DR-TB), bedaquiline and delamanid, in the current pharmaceutical research and development (R&D) paradigm, and the failure of the regulatory approval process to define the drugs’ role in multidrug regimens to improve treatment outcomes.